Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · CRESTCHEM LTD. · 29 October 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
CRESTCHEM LTD.
BSE: 526269
Commodities › Chemicals › Chemicals & Petrochemicals › Specialty Chemicals

CRESTCHEM LTD.

StateQ1 FY27 filed
Last close · 28 Oct 2026₹142.10
Market cap₹0.0k cr
TTM P/E · P/B · EV/EBITDA— · 4.30 · —

A specialty chemicals company that earns revenue from a single reported segment called Nutrition-Chemical Industries, supplying chemicals used in nutrition applications. FY26 revenue was Rs 29.61 cr, net profit was Rs 2.71 cr, and EBITDA margin was 12.96%. Raw materials dominate the cost structure at 77.9% of revenue, with employee costs at 4% and other operating expenses at 7.3%, while depreciation is barely 0.2% of revenue and capex is 0% of revenue, indicating a low fixed-asset, trading-leaning profile. The Nutrition-Chemical Industries segment accounted for 100% of segment revenue in the YTD period ending September 2023, generating Rs 8.27 cr in that period. The company is setting up a 75%-owned subsidiary, Oleo Biosciences Private Limited, in Bangalore, Karnataka, which will manufacture oleo chemicals (specialty chemicals) and is currently installing a pilot plant and laboratory equipment, with commercial production expected to begin in FY26-27 and FY27-28. The board has approved an investment of up to Rs 2.25 crore in this subsidiary. AR · MarketPing reader · 2026-08-02

Revenue streams, as the annual report describes them. Nutrition-Chemical Industries (100%). Small, single-segment specialty chemicals business with a low fixed-asset, materials-heavy cost structure

What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.

Exhibit 1: Financial summary, FY26–FY26 (all audited; no estimate years)

₹ crore · consolidatedFY26
Revenue30
EBITDA (ex other income)3
margin %10.7
Owners' profit0
EPS, as reported (₹)9.03
ROE % · ROCE %27.4 · 37.8
Debt / equity (x)0.00
Cash from operations4
Capex0
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · CRESTCHEM LTD. · 29 October 2026Page 2 of 3

Exhibit 2: Quarterly performance, last 2 quarters

₹ croreQ4 FY26Q1 FY27
Revenue109
Profit before tax21
Net profit11
EPS (₹)3.673.14
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.

Exhibit 3: Peers — basic industry group, by market cap

CompanyM.cap ₹ crP/EP/BEV/EBITDAROE %ROCE %Rev CAGR 5y %EBITDA m. %
PIDILITE INDUSTRIES LTD1,42,09553.612.8637.622.428.014.928.6
SRF LTD69,65932.24.9621.613.113.113.425.2
GUJARAT FLUOROCHEM LTD47,07576.85.9537.47.38.713.527.7
NAVIN FLUORINE INT. LTD43,61055.110.9739.316.716.423.037.5
AETHER INDUSTRIES LIMITED20,90588.68.5156.88.911.4—33.8
DEEPAK NITRITE LTD20,25725.93.4521.09.410.212.621.5
AARTI INDUSTRIES LTD15,87129.92.6717.17.04.413.016.2
FINE ORGANIC IND. LTD.15,60435.65.8625.515.720.015.928.8
Source: exchange data and filed statements via the screener; multiples at current prices.

Exhibit 4: Where the company sits in its group

MetricCompanyGroup medianRankBetter than
P/E (TTM)20.923.143 of 9957%
P/B4.32.872 of 9928%
ROCE37.710.13 of 10698%
ROE27.48.14 of 9997%
Debt / Equity0.00.21 of 9986%
EBITDA margin14.415.553 of 9947%
Market cap4369994 of 10813%
Source: MarketPing peer ranks; a rank is a measurement, not a view.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · CRESTCHEM LTD. · 29 October 2026Page 3 of 3

Exhibit 5: Filings of the last 90 days, with the measured price reaction

Date · filingCategoryImportanceNext day %5-day %
28 Oct 2026 · Crestchem board to approve September 2026 quarterly and half-year resultsboard shareholder meetingslow——
16 Oct 2026 · Crestchem clarifies price movement to BSEregulatory legalmedium——
14 Oct 2026 · BSE seeks clarification on sharp price movementregulatory legalmedium——
8 Oct 2026 · Routine dematerialisation confirmation filing for Sep 2026 quartercomplianceminimal——
26 Sept 2026 · Crestchem closes trading window ahead of Q2 resultscomplianceminimal——
8 Sept 2026 · Crestchem appoints Compliance Officer and Assistant Company Secretarymanagement changesmedium——
3 Sept 2026 · Board meeting on Sep 8 to appoint Assistant Company Secretary and Compliance Officermanagement changeslow——
14 Aug 2026 · Crestchem files Q1 FY26 results newspaper ad with BSEcomplianceminimal——
12 Aug 2026 · Crestchem Q1 FY27 results: Revenue up 82%, PAT jumps 182% YoYresultshigh——
8 Aug 2026 · 34th AGM held via video conferencing; voting results awaitedboard shareholder meetingslow——
Source: exchange announcements; each reaction is measured from the close before the filing. Next day = the close one session after the reaction day (the first session that could trade the filing).

How to read this document

Where a broker report showsThis document showsWhy
A rating (BUY / ADD / REDUCE / SELL)A state: the latest filed quarter and the measured reactionsan event is a fact; a rating is an opinion that requires SEBI RA registration
A target price and upsideThe current price and the multiples against the groupa target is a forecast; a multiple is a measurement
Estimate years marked EMore audited years; no estimatesMarketPing publishes no forecasts — your own model lives on the Models page

Sources, method and disclosures

This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.

Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in